Kardigan is a clinical-stage biopharmaceutical company developing precision medicines for cardiovascular diseases. The company targets underlying biological drivers of heart disease rather than managing symptoms. Kardigan’s pipeline includes three lead candidates in clinical trials. Danicamtiv is an oral cardiac myosin activator for genetic dilated cardiomyopathy caused by specific gene mutations. Ataciguat is an oral drug intended to slow the calcification process in patients with moderate calcific aortic valve stenosis. Tonlamarsen is an injectable antisense oligonucleotide for blood pressure management in patients hospitalized with acute severe hypertension. All three programs are in Phase 2 or Phase 3 trials, with data readouts expected in 2027. Kardigan also uses its Prolaio platform, which employs wearable biosensors and AI algorithms to collect real-world cardiovascular data from trial participants for exploratory purposes. As a pre-revenue company, Kardigan funds operations through equity financing and currently lacks commercial infrastructure. If its drugs receive approval, Kardigan would generate revenue from sales to patients and healthcare systems, though it owes royalty and milestone payments to licensors including Bristol-Myers Squibb and Ionis.